Logan Lutton

Here’s what you missed this week on Managed Healthcare Executive.

Extreme weather leads to autoimmune disease flare-ups, which can cause a loss of refrigerated medication, according to the results of recent research from the Autoimmune Association.

An experienced team of healthcare providers used to working together will likely be more successful when treating a postpartum hemorrhage, according to Abigail Wooldridge, assistant professor of Industrial and Enterprise Systems Engineering at The University of Illinois.

This is the first FDA-approved CD19- and CD20-targeted immunotherapy combination for adult patients with follicular lymphoma (FL) and the second indication for Monjuvi.

More than 99% effective at preventing HIV in trials, Yeztugo (lenacapavir) is now the first and only twice-yearly option for pre-exposure prophylaxis (PrEP).

CSL Behring’s Andembry is now approved as a subcutaneous, self-injection for hereditary angioedema (HAE) patients ages 12 and older and will be available by the end of June 2025.

Nancy Hoyt Taff, M.P.H., is the senior product manager of Medicaid at UCare, an independent, nonprofit health plan providing healthcare and administrative services to more than 600,000 members throughout Minnesota and parts of western Wisconsin.

Headspace has debuted a virtual therapy service called Therapy by Headspace that blends licensed care with AI support and insurance access to improve affordability and reach, according to a news release.

Aldeyra has resubmitted its new drug application for reproxalap, an investigational dry eye treatment, which contained new data from an additional FDA-requested trial.

Proposed Medicaid cuts by the House Budget Committee could result in 7.6 million more uninsured Americans and more than 16,000 preventable deaths annually, according to a new analysis published in the Annals of Internal Medicine.

Semaglutide appears to reduce the risk of death, heart attack and stroke in adults with type 2 diabetes more effectively than empagliflozin and dulaglutide, according to a study published in the Annals of Internal Medicine.

Here’s what you missed this week on Managed Healthcare Executive.

The FDA has accepted a New Drug Application for zoliflodacin, a first-in-class oral antibiotic for treating uncomplicated gonorrhea, offering a potential new option amid rising antibiotic resistance.

Amanda M. Shafton, CNM, DNP, FACNM, advocates for more midwives in the U.S. healthcare system, arguing that many other countries already see their value.

A new study found that implementing a specialty pharmacy program at St. Jude Children’s Research Hospital helped more young HIV patients achieve medication adherence and undetectable viral loads.

Ronanki says the differentiators for Lyric are a subscription-based model; being a platform that allows for technology integration and scale; and transparency.

Ibtrozi had a 90% response rate in treatment naïve adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer, according to the results of a news release.

Enflonsia is the first FDA-approved respiratory syncytial virus (RSV) preventative for infants, regardless of weight, according to the news release.

Ben Scharfe, CPA, shares how his career-changing advice came from an unlikely person.

The United States has twice the postpartum hemorrhage mortality rate of other developed countries, which is why it’s essential to create and maintain safety protocols during obstetric emergencies, according to Abigail Wooldridge, assistant professor of Industrial and Enterprise Systems Engineering at The University of Illinois.

Patrick Roberts, Pharm.D., said his career changed when he listened to a mentor encouraging him to go back to school.

Kate Masino, MBA, says her career path was changed while watching her chronically ill, aging parents try to navigate the U.S. healthcare system.

Although some HIV programs will remain, the proposed cuts in the fiscal year 2026 budget are too severe and will hinder HIV care and research in the United States, according to Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C.

Gen Z was the age group most likely to spend the money on GLP-1 agonists; still, only 27% would.

Justin Jasniewski, MBA, shared a story about his career turning point and how it involved a rejected proposal and a Big Three PBM seven-figure check.

Here’s what you missed this week on Managed Healthcare Executive.

Cassie Houff, MBA, says the most impactful change for U.S. healthcare would be “an overhaul to the fee-for-service payment system,” arguing that it doesn’t incentivize timely or necessary care.